StockData
Emmaus Life Sciences, Inc. logo

Emmaus Life Sciences, Inc. (EMMA) stock

EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.05−0.01 (-14.38%)

Close on Oct 19, 2026Market cap $6.03MP/E –Yield –

Emmaus Life Sciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Emmaus Life Sciences's operating cash flow for the twelve months ending Jun 30, 2026 was $3.97M. For fiscal 2025 it was -$11.00K. The highest annual figure on record is -$11.00K in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.00K–
FY2024Dec 31, 2024-$2.29M–
FY2023Dec 31, 2023-$1.50M–
FY2022Dec 31, 2022-$5.07M–
FY2021Dec 31, 2021-$1.25M–
FY2020Dec 31, 2020-$2.45M–
FY2019Dec 31, 2019-$4.52M–
FY2017Sep 30, 2017-$4.79M–
FY2016Sep 30, 2016-$2.98M–
FY2015Sep 30, 2015-$2.16M–
FY2014Sep 30, 2014-$3.27M–
FY2013Sep 30, 2013-$3.04M–
FY2012Sep 30, 2012-$2.34M–
FY2011Sep 30, 2011-$3.57M–
FY2010Sep 30, 2010-$4.91M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$1.69M+393.6%
Q1 FY2026CQ1 2026Mar 31, 2026-$344.00K-332.4%
Q4 FY2025CQ4 2025Dec 31, 2025$2.21M–
Q3 FY2025CQ3 2025Sep 30, 2025$409.00K+192.1%
Q4 FY2024CQ4 2024Dec 31, 2024$343.00K-66.9%
Q3 FY2024CQ3 2024Sep 30, 2024$148.00K+155.2%
Q2 FY2024CQ2 2024Jun 30, 2024-$2.92M–
Q1 FY2024CQ1 2024Mar 31, 2024$140.00K–
Q4 FY2023CQ4 2023Dec 31, 2023$1.04M-38.2%
Q3 FY2023CQ3 2023Sep 30, 2023$58.00K–
Q2 FY2023CQ2 2023Jun 30, 2023-$1.31M–
Q1 FY2023CQ1 2023Mar 31, 2023-$1.29M–
Q4 FY2022CQ4 2022Dec 31, 2022$1.68M+93.9%
Q3 FY2022CQ3 2022Sep 30, 2022-$954.00K-158.2%
Q2 FY2022CQ2 2022Jun 30, 2022-$1.06M-539.3%
Q1 FY2022CQ1 2022Mar 31, 2022-$4.73M–
Q4 FY2021CQ4 2021Dec 31, 2021$865.00K-54.7%
Q3 FY2021CQ3 2021Sep 30, 2021$1.64M–
Q2 FY2021CQ2 2021Jun 30, 2021$242.00K–
Q1 FY2021CQ1 2021Mar 31, 2021-$4.00M-321.3%
Q4 FY2020CQ4 2020Dec 31, 2020$1.91M–
Q3 FY2020CQ3 2020Sep 30, 2020-$2.64M–
Q2 FY2020CQ2 2020Jun 30, 2020-$3.53M–
Q1 FY2020CQ1 2020Mar 31, 2020$1.81M–
Q4 FY2019CQ4 2019Dec 31, 2019-$3.26M–
Q3 FY2019CQ3 2018Jun 30, 2019-$81.00K–
Q4 FY2017CQ3 2017Sep 30, 2017-$2.12M–
Q3 FY2017CQ2 2017Jun 30, 2017-$1.07M–
Q2 FY2017CQ1 2017Mar 31, 2017-$835.30K–
Q1 FY2017CQ4 2016Dec 31, 2016-$765.80K–
Q4 FY2016CQ3 2016Sep 30, 2016-$948.50K–
Q3 FY2016CQ2 2016Jun 30, 2016-$690.00K–
Q2 FY2016CQ1 2016Mar 31, 2016-$732.40K–
Q1 FY2016CQ4 2015Dec 31, 2015-$607.50K–
Q4 FY2015CQ3 2015Sep 30, 2015-$443.80K–
Q3 FY2015CQ2 2015Jun 30, 2015-$368.90K–
Q2 FY2015CQ1 2015Mar 31, 2015-$550.00K–
Q1 FY2015CQ4 2014Dec 31, 2014-$793.70K–

More Emmaus Life Sciences figures

See a number that looks wrong?